Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease.

Kristoffer Nilsson,Emelie Andersson,Sofie Persson,Kristina Karlsdotter,Josefin Skogsberg,Staffan Gustavsson,Johan Jendle,Katarina Steen Carlsson

Diabetes, obesity & metabolism（2023）

引用 0|浏览12

暂无评分

摘要

Model simulations using real-world data and trial treatment effects indicated that a broader implementation of empagliflozin, in line with current guidelines for treatment of people with type 2 diabetes and eCVD, would lead to further benefits even from a short-term perspective.

查看译文

关键词

empagliflozin,diabetes,budget impact,health benefits

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要